Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 608-616

  Oh, J ^a   Shin, D ^a   Lim, K S ^a   Lee, S ^a   Jung, K H ^b   Chu, K ^b   Hong, K S ^b   Shin, K H ^c   Cho, J Y ^a   Yoon, S H ^a   Ji, S C ^a   Yu, K S ^a   Lee, H ^a   Jang, I J ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG METABOLITE; H 4; MICRORNA; MICRORNA 27A; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MODULATION; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN FOLDING; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENOSINE DIPHOSPHATE; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; ASPIRIN; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RNA, MESSENGER; TICLOPIDINE;

EID: 84901244467     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.49     Document Type: Article

References (33)

1. Gurbel, P.A., Bliden, K.P., Hiatt, B.L. & O'Connor, C.M. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003
2. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011
3. Ganesan, S., Williams, C., Maslen, C.L. & Cherala, G. Clopidogrel variability: Role of plasma protein binding alterations. Br. J. Clin. Pharmacol. 75, 1468-1477 (2013
4. Gong, I.Y. et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur. Heart J. 33, 2856-2464a (2012
5. Jung, K.H. et al. Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin. Pharmacol. Ther. 90, 612-619 (2011
6. Kim, K.A., Park, P.W., Hong, S.J. & Park, J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84, 236-242 (2008
7. Ohmori, T. et al. Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thromb. Res. 129, e36-e40 (2012
8. Scott, S.A. et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013
9. Taubert, D. et al. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 80, 486-501 (2006
10. Umemura, K., Furuta, T. & Kondo, K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J. Thromb. Haemost. 6, 1439-1441 (2008
11. Sangkuhl, K., Klein, T.E. & Altman, R.B. Clopidogrel pathway. Pharmacogenet. Genomics 20, 463-465 (2010
12. Kazui, M. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92-99 (2010
13. Holmberg, M.T., Tornio, A., Neuvonen, M., Neuvonen, P.J., Backman, J.T. & Niemi, M. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin. Pharmacol. Ther. 95, 307-313 (2014
14. Siller-Matula, J.M., Spiel, A.O., Lang, I.M., Kreiner, G., Christ, G. & Jilma, B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1-148.e5 (2009
15. Angiolillo, D.J. et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 89, 65-74 (2011
16. Furuta, T., Iwaki, T. & Umemura, K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br. J. Clin. Pharmacol. 70, 383-392 (2010
17. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009
18. Lewis, J.P. et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin. Pharmacol. Ther. 90, 568-574 (2011
19. Talameh, J.A. & McLeod, H.L. PON1 Q192R and clopidogrel: A case of the winner's curse or inadequate replication? Clin. Pharmacol. Ther. 90, 771-774 (2011
20. Maree, A.O. & Fitzgerald, D.J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115, 2196-2207 (2007
21. Rotem, R., Tzivony, Y. & Flescher, E. Contrasting effects of aspirin on prostate cancer cells: Suppression of proliferation and induction of drug resistance. Prostate 42, 172-180 (2000
22. Flescher, E., Rotem, R., Kwon, P., Azare, J., Jaspers, I. & Cohen, D. Aspirin enhances multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells. Anticancer Res. 20, 4441-4444 (2000
23. Price, M.J., Coleman, J.L., Steinhubl, S.R., Wong, G.B., Cannon, C.P. & Teirstein, P.S. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am. J. Cardiol. 98, 681-684 (2006
24. Farid, N.A., Kurihara, A. & Wrighton, S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50, 126-142 (2010
25. Karazniewicz-Lada, M. et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin. Pharmacokinet. 53, 155-164 (2014
26. Caplain, H., Donat, F., Gaud, C. & Necciari, J. Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost. 25 (suppl. 2), 25-28 (1999
27. Bae, S.K. et al. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatographytandem mass spectrometry: Application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed. Chromatogr. 22, 590-595 (2008
28. Zhu, H. et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76, 582-588 (2008
29. Bhattacharyya, T. et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276 (2008
30. Blatter-Garin, M.C., Kalix, B., De Pree, S. & James, R.W. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 46, 593-594 (2003
31. Jaichander, P., Selvarajan, K., Garelnabi, M. & Parthasarathy, S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J. Lipid Res. 49, 2142-2148 (2008
32. Roh, H.K., Dahl, M.L., Tybring, G., Yamada, H., Cha, Y.N. & Bertilsson, L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6, 547-551 (1996
33. Richter, W., Erenmemisoglu, A., Van der Meer, M.J., Emritte, N., Tuncay, E. & Koytchev, R. Bioequivalence study of two different clopidogrel bisulfate filmcoated tablets. Arzneimittelforschung. 59, 297-302 (2009